RxDoctor Payments Data

Zachary Gokie, PA

Medical · Lincoln, NENPI 1528630811

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 26.4% of the total.

$1,146in general payments, 2019–2025

Across 81 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$303
  • Boehringer Ingelheim$273
  • Pfizer$160
  • Johnson & Johnson$157
  • Abiomed$112
  • AstraZeneca$84
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$1,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,146 in reported general payments places this provider in the 70th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$11,014
Medicare patients
127
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$33,499
XareltoRivaroxaban31$22,810
JardianceEmpagliflozin18$9,923
BrilintaTicagrelor15$6,886
FarxigaDapagliflozin Propanediol11$6,091
ClopidogrelClopidogrel Bisulfate124$750
Atorvastatin Calcium68$677
Metoprolol Succinate121$636
Potassium Chloride35$403
Amlodipine Besylate48$267
Furosemide68$264
Carvedilol35$254
Pantoprazole Sodium40$222
Isosorbide Mononitrate ErIsosorbide Mononitrate13$166
Nitroglycerin18$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$33,49955 claims
Johnson & JohnsonXarelto$157$22,81031 claims
AstraZenecaBrilinta, Farxiga$84$12,97726 claims
Boehringer IngelheimJardiance$273$9,92318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 216 medical providers in Nebraska.

Other medical in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →